切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2021, Vol. 15 ›› Issue (03) : 314 -318. doi: 10.3877/cma.j.issn.1674-3946.2021.03.022

所属专题: 文献

论著

超声联合肿瘤标记物对cN0期甲状腺微小乳头状癌中央区淋巴结隐匿性转移的预测价值
许思哲1,(), 贺功建1, 曾黎1, 杨蕙嘉1, 王芳1   
  1. 1. 638000 四川广安,四川大学华西广安医院甲乳外科
  • 收稿日期:2020-07-20 出版日期:2021-06-26
  • 通信作者: 许思哲

The predictive value of ultrasonography combined with tumor markers for occult lymph node metastasis in central area of cN0 stage micropapillary thyroid carcinoma

Sizhe Xu1,(), Gongjian He1, Li Zeng1, Huijia Yang1, Fang Wang1   

  1. 1. Department of Breast Surgery, West China Guang’an Hospital, Sichuan University, Guangan 638000, China
  • Received:2020-07-20 Published:2021-06-26
  • Corresponding author: Sizhe Xu
  • Supported by:
    Sichuan Popularization Application Project(17PJ180); Sichuan Provincial Health Appropriate Technology Extension Project(19SYJS103)
引用本文:

许思哲, 贺功建, 曾黎, 杨蕙嘉, 王芳. 超声联合肿瘤标记物对cN0期甲状腺微小乳头状癌中央区淋巴结隐匿性转移的预测价值[J/OL]. 中华普外科手术学杂志(电子版), 2021, 15(03): 314-318.

Sizhe Xu, Gongjian He, Li Zeng, Huijia Yang, Fang Wang. The predictive value of ultrasonography combined with tumor markers for occult lymph node metastasis in central area of cN0 stage micropapillary thyroid carcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(03): 314-318.

目的

探究超声联合肿瘤标记物对cN0期甲状腺微小乳头状癌(PTMC)颈中央区淋巴结转移(CLNM)的临床预测价值。

方法

回顾性选取2018年5月至2020年4月行预防性中央区淋巴结清扫术的187例cN0-PTMC患者分为CLNM转移阳性组(+)和阴性组(-)。采用SPSS 19.0进行数据分析,计量资料采用(±s)表示,计数资料采用n(%)表示,P<0.05为检验标准。经单因素及Logistic回归多因素分析CLNM转移独立危险因素,建立联合预测模型,绘制ROC曲线,计算AUC值,评估预测模型诊断效能。

结果

187例cN0-PTMC患者CLNM转移率为36.4%(68/187)。经单、多因素分析显示,肿瘤直径>7 mm、BRAFV600E基因突变阳性、多癌灶及包膜侵犯是cN0-PTMC患者发现CLNM的独立危险因素(P<0.05)。通过建立联合预测模型,当Y取0.722时诊断价值最高,灵敏度为88.9%,特异度为83.3%。Hosmer-Lemeshow拟合优度检验预测模型的P值为0.579,该模型预测CLNM的结果与术后病理确诊的一致性良好,Kappa=0.721,P=0.000。

结论

超声特征联合肿瘤分子标记物预测cN0-PTMC发生CLNM具有良好的诊断灵敏度及特异度,可为临床术式的选择提供指导依据。

Objective

To investigate the clinical predictive value of ultrasound combined with tumor markers for lymph node metastasis (CLNM) in the central cervical region of cN0 thyroid micropapillary carcinoma (PTMC).

Methods

A retrospective study of 187 patients with CN0-PTMC who underwent preventive central lymph node dissection from May 2018 to April 2020 were retrospectively selected and divided into two groups: CLNM metastatic positive group (+ ) and the NegativeEGATIVE group (-). SPSS 19.0 was used for data analysis., Mmeasurement data were expressed as (±s), counting data as n(%), and P<0.05 was the test standard. The singleindependent risk factor s of CLNM transfer were analyzed by univariate and Logistic regression factor were used to analyze the independent risk factors of CLNM transfer. s, Tthe joint prediction model was established, the ROC curve was drawn, the AUC value was calculated, and the diagnostic efficiency of the prediction model was evaluated.

Results

The CLNM metastasis rate of 187 patientsCLNM in 187with CN0-PTMC patients was 36.4%(68/187). Single and multivariate analysis showed that tumor diameter of > 7 mm, positive BRAFV600E mutation, multiple foci and capsule invasion were independent risk factors for CLNM detection in patients with cn0-ptmc (P<0.05). By establishing the joint prediction model, when Y is 0.722, the diagnostic value is the highest, the sensitivity is 88.9%, and the specificity is 83.3%. The Predictive model of Hosmer-Lemeshow goodness of fit test showeshad a P value of 0.579, and the indicating that the predicted results of CLNM by the model were in good agreement with postoperative pathological diagnosis, Kappa=0.721, P=0.000.

Conclusion

Ultrasonographic features combined with tumor molecular markers canto predict the occurrence of CLNM of CN0-PTMC have with good diagnostic sensitivity and specificity, which can provide guidance for the selection of clinical operation.

图1 ARMS法检测cN0-PTMC患者BRAFV600E基因突变图[注:A:15号外显子目的基因凝胶电泳图(224bp);B:BRAFV600E突变外控扩增信号]
表1 187例cN0-PTMC患者CLNM单因素分析[例(%)]
表2 cN0-PTMC患者中央区淋巴结转移多因素分析
图2 超声联合BRAFV600E基因检测预测PTMC患者CLNM的ROC曲线
表3 cN0-PTMC患者CLNM预测模型的各变量赋值说明
[1]
林前煌,徐慧,郇金亮.甲状腺微小乳头状癌诊治进展[J].实用肿瘤学杂志,2017,31(1): 61-64.
[2]
Price AK, Randle RW, Schneider DF, et al. Papillary thyroid microcarcinoma: decision-making, extent of surgery, and outcomes[J]. J Surg Res, 2017, 218: 237-245.
[3]
乔娜,白雪巍,王刚,等. cN0期甲状腺乳头状癌预防性中央区淋巴结清扫的争议与进展[J].中国普通外科杂志,2016,25(5): 729-734.
[4]
Miyauchi A, Ito Y, Oda H. Insights into the management of papillary microcarcinoma of the thyroid[J]. Thyroid, 2018, 28(1): 23-31.
[5]
于淏,王强,查斯洛,等. 5mm及以下cN0甲状腺乳头状微小癌中央区淋巴结转移规律及危险因素分析[J].第二军医大学学报,2018,39(1): 101-104.
[6]
徐上妍,贾晓红,倪晓枫,等. 术前临床及超声特征预测临床淋巴结阴性甲状腺乳头状癌中央组淋巴结转移的价值[J].中华超声影像学杂志,2019,28(8): 675-679.
[7]
丁金旺,罗定存,荀延萍,等.基于ARMS法检测BRAFV600E突变在甲状腺乳头状癌中的临床价值[J].中国耳鼻咽喉头颈外科,2017,24(2): 71-75.
[8]
朱乔丹,欧笛,杨菁,等. 甲状腺乳头状癌颈部淋巴结转移风险评估的研究现状[J/CD].中华医学超声杂志(电子版),2019,16(11): 880-884.
[9]
Akin S, Aksoy DY, Aksoy Y,et al. Prediction of central lymph node metastasis in patientswith thyroid papillary microcarcinoma [J]. Turk J Med Sci, 2017, 47(6): 1723-1727.
[10]
侯卫华,李从洋,孟祥超,等.免疫组化蛋白标志物在甲状腺乳头状癌组织中的表达[J].肿瘤基础与临床,2018,31(3): 192-195.
[11]
Chen YF, Sadow PM, Suh HS, et al. BRAF (V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta Analysis[J]. Thyroid, 2016, 26(2): 248-255.
[12]
贺亚萍,徐辉雄.超声引导细针穿刺抽吸活组织检查联合分子标志物诊断甲状腺肿瘤的进展[J/CD].中华医学超声杂志(电子版),2015,12(10): 753-756.
[13]
武元元,王军,毛爱红,等.甲状腺乳头状癌中央区淋巴结转移评分系统的建立及验证[J].中国癌症防治杂志,2019,11(6): 498-502.
[14]
张奥博,刘良发,路承,等. cN0期甲状腺乳头状癌患者颈部中央区淋巴结转移的危险因素分析[J].临床耳鼻咽喉头颈外科杂志,2017,31(15): 1141-1145.
[15]
Lanzilotta SG, Grammatica L, Paradiso A,et al. BRAF in Papillary Thyroid Carcinoma[J]. Cellular Oncology, 2007, 29(4): 269-277.
[16]
张晶晶,赵艳萍,肖雄,等. BRAFV600E突变与甲状腺微小乳头状癌生物学行为关联的Meta分析[J].中华核医学与分子影像杂志,2018,38(3): 199-204.
[17]
郝少龙,刘新承,马纪红,等.甲状腺乳头状癌组织TSHR表达与BRAFV600E基因突变的关系研究[J/CD].中华普外科手术学杂志(电子版),2018,12(6): 468-471.
[1] 章建全, 程杰, 陈红琼, 闫磊. 采用ACR-TIRADS评估甲状腺消融区的调查研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 966-971.
[2] 罗辉, 方晔. 品管圈在提高甲状腺结节细针穿刺检出率中的应用[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 972-977.
[3] 杨忠, 时敬业, 邓学东, 姜纬, 殷林亮, 潘琦, 梁泓, 马建芳, 王珍奇, 张俊, 董姗姗. 产前超声在胎儿22q11.2 微缺失综合征中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 852-858.
[4] 汪洪斌, 张红霞, 何文, 杜丽娟, 程令刚, 张雨康, 张萌. 低级别阑尾黏液性肿瘤与阑尾黏液腺癌超声及超声造影特征分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 865-871.
[5] 孙佳丽, 金琳, 沈崔琴, 陈晴晴, 林艳萍, 李朝军, 徐栋. 机器人辅助超声引导下经皮穿刺的体外实验研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 884-889.
[6] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[7] 李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[8] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[9] 奚玲, 仝瀚文, 缪骥, 毛永欢, 沈晓菲, 杜峻峰, 刘晔. 基于肌少症构建的造口旁疝危险因素预测模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 48-51.
[10] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[11] 麻紫月, 王贞文, 张强, 赵代伟, 张翊伦. 右侧喉不返神经1例报告[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 115-116.
[12] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[13] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[14] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要